EDITOR—Pollock et al clearly summarise the problems inherent in the UK Department of Health's new research strategy.1 2 The proposed reorganisation of primary care research networks is also a concern: pharmaceutical industry representatives may have membership of key strategic groups in reorganised primary care networks and the predominant research paradigm will become the large randomised controlled trial.

One of the clear strengths of the current networks …